Potential underuse of cardiac tests in heart failure, an antidote for prolonged sitting, and a new practice advisory from the AAN on patent foramen ovale (PFO) closure and stroke.

Cardiovascular electrophysiologists at Mayo delve into implantable cardioverter defibrillator tracings and provide tips on how to interpret them

Dr Wharton quotes baseball legend Yogi Berra in this narrated case: In theory there is no difference between theory and practice. In practice there is.

European vs US standards for device approval, action plan for drugs that exacerbate HF, the Mediterranean diet, Entresto/LCZ696, and a poignant essay from Melissa Walton-Shirley are discussed.

TAVR with the SAPIEN 3 valve, Obesity and premature death, new CMS reimbursement rules, race and AF, and heart failure with preserved EF are discussed by Dr John Mandrola in this week's podcast.

Absorbable stents, statin titration vs LDL-C targets, end-of-life care, decision support in patients with heart failure, and diabetes prevention with exercise are reviewed in this week's podcast.

Insulin-Statin-PCSK9 linkage, QOL on warfarin, ticagrelor adherence, cardio-protection for Breast CA Rx, Brugada Syndrome and AF ablation as a placebo are discussed by Dr Mandrola in this week's podcast.

The LEADER diabetes trial, remote-monitoring preferences, avoidable stroke burden, air pollution, and two AF ablation trials (FIRE and ICE secondary analysis and ICE-T) are reviewed this week.

Removal of leadless pacemakers, APEX trial, the Mediterranean diet, music therapy, and inequalities in TAVI use worldwide are discussed by Dr Mandrola in this week's podcast.

Potential risk for cancer diagnosis after AF, the merits of low-Na policies, Tai Chi effects on BP, and the unseen bias of medical organizations in guidelines are discussed in this week's podcast.